Gracey Craig sold $120K of OMDA

Gracey Craig (Chief Accounting Officer) sold 6,894 shares of Omada Health, Inc. (OMDA) at $17.42 ($0.12M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Jun 16, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on officer ownership changes, but the 10b5-1 designation reduces interpretive weight.

02

Market read

Traders may note the insider sale for sentiment/positioning, but it is unlikely to be a standalone fundamental catalyst.

03

What to watch

The filing date (6/16) may drive a brief sentiment reaction, but the economic substance is the pre-arranged nature and relatively small transaction size.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-16; sale dated 2026-06-12.

Background

The article is an SEC Form 4 insider transaction disclosure for Omada Health, Inc.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CFO Gracey Craig sold 6,894 shares in an open-market transaction worth about $120.1K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction would be short-lived.

Evidence & confidence

The disclosure is a standard officer sale with a stated pre-arranged 10b5-1 plan and modest dollar value relative to typical market impact.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term risk or liquidity needs; traders may watch for follow-on sales.

Key entities

  • Omada Health, Inc.

    Company whose officer transaction is disclosed on SEC Form 4.

  • Gracey Craig

    Chief Accounting Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.